益气通络方对2型糖尿病患者疗效的影响

doi:10.3760/cma.j.cn441417-20240309-002006

摘要/Abstract

摘要：

目的　观察益气通络方对2型糖尿病（type 2 diabetes mellitus，T2DM）患者血清载脂蛋白B（apolipoprotein B，ApoB）、载脂蛋白A-Ⅰ（apolipoprotein A-Ⅰ，ApoA-Ⅰ）、胰高血糖素样肽-1 （glucagon-like peptide-1，GLP-1）水平及糖代谢的影响。方法　选取商洛市中心医院2020年8月至2023年8月收治的98例T2DM患者进行随机对照试验。采用随机数字表法将其分为对照组和观察组，每组49例。对照组男24例，女25例，年龄（47.85±6.14）岁，病程（8.34±2.48）年。观察组男22例，女27例，年龄（46.59±6.03）岁，病程（8.56±2.25）年。对照组在常规治疗的基础上加用甲钴胺片，观察组在对照组基础上加用益气通络方；两组均治疗2个月。比较两组临床疗效，中医证候积分，血清ApoB、ApoA-Ⅰ、GLP-1水平，糖代谢，下肢神经传导速度，不良反应。采用χ²检验和t检验进行统计分析。结果　观察组总有效率高于对照组［95.92%（47/49）比79.59%（39/49）；χ²=6.078，P<0.05］。观察组中医证候积分总分低于对照组［（3.89±1.03）分比（4.94±1.21）分］，差异有统计学意义（t=4.625，P<0.05）。观察组ApoB水平低于对照组［（0.94±0.17）g/L比（1.05±0.25）g/L］，ApoA-Ⅰ、口服葡萄糖耐量试验（oral glucose tolerance test，OGTT）0 min GLP-1、OGTT 2 h GLP-1水平均高于对照组［（1.18±0.21）g/L比（1.06±0.15）g/L、（132.47±15.21）g/L比（118.37±16.45）g/L、（154.23±21.43）mol/L比（125.91±23.59）mol/L］，差异均有统计学意义（t=2.547、3.255、5.030、8.636，均P<0.05）。观察组空腹血糖（fasting blood glucose，FBG）、餐后1 h血糖（postprandial 1 h blood glucose，1hPBG）、餐后2 h血糖（postprandial 2 h blood glucose，2hPBG）、糖化血红蛋白（hemoglobin A1c，HbA1c）水平均低于对照组［（6.51±0.82）mmol/L比（7.49±1.18）mmol/L、（8.53±1.19）mmol/L比（9.04±1.05）mmol/L、（10.57±1.38）mmol/L比（11.26±1.43）mmol/L、（6.17±0.52）%比（6.96±0.68）%］，差异均有统计学意义（t=4.774、2.250、2.430、6.460，均P<0.05）。观察组正中神经运动神经传导速度（motor nerve conduction velocity，MNCV）、感觉神经传导速度（sensory nerve conduction velocity，SNCV）和腓总神经MNCV、SNCV均高于对照组［（47.24±2.58）m/s比（44.32±3.14）m/s、（47.25±3.73）m/s比（45.09±3.26）m/s、（43.58±4.33）m/s比（41.04±4.51）m/s、（42.10±3.45）m/s比（39.61±3.27）m/s］，差异均有统计学意义（t=5.030、3.052、2.844、3.667，均P<0.05）。结论　益气通络方联合甲钴胺片能提高T2DM患者临床疗效，改善患者血清因子水平及糖代谢，加快患者下肢神经传导速度。

关键词:

2型糖尿病, 益气通络方, 载脂蛋白, 胰高血糖素样肽-1, 糖代谢

Abstract:

Objective　To observe the effects of Yiqi Tongluo Formula on serum levels of apolipoprotein B (apoB), apolipoprotein A-Ⅰ (ApoA-Ⅰ), and glucagon-like peptide 1 (GLP-1) and glucose metabolism in patients with type 2 diabetes mellitus (T2DM). Methods　A total of 98 patients with T2DM treated at Shangluo Central Hospital from August 2020 to August 2023 were selected for the randomized controlled trial. They were divided into a control group and an observation group by the random number table method, with 49 cases in each group. There were 24 males and 25 females in the control group; they were (47.85±6.14) years old; their disease course was (8.34±2.48) years. There were 22 males and 27 females in the observation group; they were (46.59±6.03) years old; their disease course was (8.56±2.25) years. The control group took conventional treatment and mecobalamin tablets, and the observation group conventional treatment, mecobalamin tablets, and Yiqi Tongluo Formula, for 2 months. The clinical efficacies, scores of traditional Chinese medicine syndromes, serum levels of ApoB, ApoA-Ⅰ, and GLP-1, glucose metabolism, lower limb nerve conduction velocities, and adverse reactions were compared between the two groups. χ² and t tests were used for the statistical analysis. Results　The total effective rate in the observation group was higher than that in the control group [95.92% (47/49) vs. 79.59% (39/49); χ²=6.078; P<0.05]. The total score of traditional Chinese medicine syndromes in the observation group was lower than that in the control group (3.89±1.03 vs. 4.94±1.21), with a statistical difference (t=4.625; P<0.05). The level of ApoB in the observation group was lower than that in the control group [(0.94±0.17) g/L vs. (1.05±0.25) g/L]; the levels of ApoA-Ⅰ and GLP-1 0 min and 2 h after oral glucose tolerance test (OGTT) in the observation group were higher than those in the control group [(1.18±0.21) g/L vs. (1.06±0.15) g/L, (132.47±15.21) g/L vs. (118.37±16.45) g/L, and (154.23±21.43) mol/L vs. (125.91±23.59) mol/L]; there were statistical differences (t=2.547, 3.255, 5.030, and 8.636; all P<0.05). The levels of fasting blood glucose (FBG), 1-hour postprandial blood glucose (1hPBG), 2-hour postprandial blood glucose (2hPBG), and glycated hemoglobin (HbA1c) in the observation group were lower than those in the control group [(6.51±0.82) mmol/L vs. (7.49±1.18) mmol/L, (8.53±1.19) mmol/L vs. (9.04±1.05) mmol/L, (10.57±1.38) mmol/L vs. (11.26±1.43) mmol/L, and (6.17±0.52)% vs. (6.96±0.68)%], with statistical differences (t=4.774, 2.250, 2.430, and 6.460; all P<0.05). The motor nerve conduction velocities (MNCV) and sensory nerve conduction velocities (SNCV) of median nerve and common peroneal nerve in the observation group were higher than those in the control group [(47.24±2.58) m/s vs. (44.32±3.14) m/s, (47.25±3.73) m/s vs. (45.09±3.26) m/s, (43.58±4.33) m/s vs. (41.04±4.51) m/s, (42.10±3.45) m/s vs. (39.61±3.27) m/s], with statistical differences (t=5.030, 3.052, 2.844, and 3.667; all P<0.05). Conclusion　Yiqi Tongluo Formula combined with mecobalamin tablets can improve clinical therapeutic effects on patients with T2DM, improve their serum factor levels and glucose metabolism, and accelerate their lower limb nerve conduction velocity.

Key words:

Type 2 diabetes mellitus, Yiqi Tongluo , Formula, Apolipoprotein, Glucagon-like peptide 1, Glucose metabolism

郭浩楠吴红群.

益气通络方对2型糖尿病患者疗效的影响 [J]. 国际医药卫生导报, 2025, 31(2): 203-208.

Guo Haonan, Wu Hongqun.

Effect of Yiqi Tongluo Formula on treatment efficacy in patients with type 2 diabetes mellitus [J]. International Medicine and Health Guidance News, 2025, 31(2): 203-208.

参考文献

[1] Peer N, Balakrishna Y, Durao S. Screening for type 2 diabetes mellitus[J]. Cochrane Database Syst Rev, 2020, 5(5): CD005266. DOI: 10.1002/14651858.CD005266.pub2.
[2] 卢春键,刘薇,林少霞,等. 五种常用中医外治法联合常规西药治疗糖尿病周围神经病变有效性和安全性的贝叶斯网状Meta分析[J]. 中国全科医学,2022,25(33):4106-4116. DOI: 10.12114/j.issn.1007-9572.2021.00.536.
[3] 王霞,张凌云,宋守君. 索格列净治疗2型糖尿病患者心血管并发症的研究进展[J]. 国际医药卫生导报,2024,30(13): 2141-2144. DOI: 10.3760/cma.j.issn.1007-1245.2024. 13.006.
[4] 陈鑫,张宏颖,魏凤婷,等. 连芪麦冬方联合磷酸西格列汀片对2型糖尿病心脑肾微血管病变因子影响研究[J]. 现代中西医结合杂志,2023,32(9):1269-1272, 1281. DOI: 10.3969/j.issn.1008-8849.2023.09.021.
[5] 李静,马红彦,路康,等. 益气通络安神方联合阿托伐他汀治疗高血压合并冠心病疗效及对炎症反应和血管内皮功能的影响[J]. 现代中西医结合杂志,2024,33(12):1709-1713. DOI: 10.3969/j.issn.1008-8849.2024.12.018.
[6] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志,2021,13(4):315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.
[7] 国家药物监督管理局.中药新药临床研究指导原则:试行[M].北京: 中国医药科技出版社, 2002: 233-237.
[8] 商洪才,王保和,张伯礼. 中药新药证候及疗效评价[J]. 中药新药与临床药理,2004,15(5):365-368. DOI:10.3321/j.issn:1003-9783.2004.05.024.
[9] 殷娇,常浩瀚,刘萍,等. 体重指数和血清甘油三酯与痛性糖尿病神经病变相关性的研究[J]. 中国糖尿病杂志,2023,31(1):27-30. DOI: 10.3969/j.issn.1006-6187.2023.01.007.
[10] 罗欢,朱世琴,沈玉兰,等. 基于随机森林算法的糖尿病周围神经病变预测模型构建与验证[J]. 中国糖尿病杂志,2024,32(8):591-594. DOI: 10.3969/j.issn.1006-6187. 2024.08.006.
[11] 梅海云,张永文,吴秉司,等. 基于糖代谢和胰岛素抵抗评估益气养阴法治疗气阴两虚型2型糖尿病的疗效[J]. 辽宁中医杂志,2024,51(6):123-126. DOI: 10.13192/j.issn. 1000-1719.2024.06.033.
[12] 张柂儇,刘海龙,王瑞琼,等. 黄芪化学成分和药理作用及Q-marker预测分析[J]. 中国新药杂志,2023,32(4):410-419. DOI: 10.3969/j.issn.1003-3734.2023.04.011.
[13] 郭新年,口锁堂,刘帮健. 基于Nrf2-ARE通路探讨黄芪桂枝五物汤对急性脑梗死治疗后缺血再灌注损伤的保护效应与机制[J]. 中国医院用药评价与分析,2023,23(10):1190-1194. DOI: 10.14009/j.issn.1672-2124.2023. 10.008.
[14] 畅秀丽,张安兵. 白芍总苷调控NF-κB/NLRP3信号通路对急性痛风性关节炎大鼠的影响机制研究[J]. 中国免疫学杂志,2023,39(2):313-317. DOI:10.3969/j.issn.1000- 484X. 2023.02.017.
[15] 杨秀娟,杨志军,陈建平,等. 生姜、干姜、炮姜对胃寒模型大鼠的能量代谢研究[J]. 中国临床药理学杂志,2023,39(7): 989-993. DOI: 10.13699/j.cnki.1001-6821. 2023.07.017.
[16] 马晓宁,秦令祥,冀晓龙,等. Design-Expert软件设计优化内黄大枣多糖的硒化修饰及其抗氧化、抗疲劳作用研究[J]. 食品安全质量检测学报,2023,14(10):164-172. DOI: 10.19812/j.cnki.jfsq11-5956/ts.2023.10.020.
[17] 邓成杰,马洪星,张华茜,等. 苏木酮A通过抑制JAK2-STAT3信号通路发挥抗炎作用[J]. 中药新药与临床药理,2023,34(12):1685-1690. DOI:10.19378/j.issn.1003-9783. 2023.12.005.
[18] 韩迪,程永现,晏永明. 土鳖虫药理作用研究进展[J]. 中国现代中药,2022,24(12):2501-2513. DOI: 10.13313/j.issn. 1673-4890.20220126003.
[19] 田林华,姚琳,冯丽娜,等. 广地龙纯化蛋白促进创伤修复作用机制研究[J]. 世界中医药,2023,18(9):1236-1239. DOI: 10.3969/j.issn.1673-7202.2023.09.004.
[20] 郑曲,张宇,杨永菊,等. 牛膝及其活性成分治疗骨关节炎的研究现状[J]. 中国临床药理学杂志,2023,39(20):3032-3036. DOI:10.13699/j.cnki.1001-6821.2023.20.031.
[21] 化敏,耿雪,刘月程,等. 炙甘草干预脾虚大鼠的血清代谢组学研究[J]. 中成药,2023,45(5):1710-1716. DOI:10.3969/j.issn.1001-1528.2023.05.058.
[22] 富士峰. 益气扶正通痹汤联合甲钴胺片治疗2型糖尿病周围神经病变对患者sICAM-1、Omentin-1的影响[J]. 四川中医,2021,39(8):105-108.
[23] 邵锦华,贺乐,孙瑾,等. 四妙勇安汤加减治疗2型糖尿病合并冠心病的疗效观察及对血清ApoB、ApoA-Ⅰ的影响[J]. 辽宁中医杂志,2020,47(11):123-126. DOI:10.13192/j.issn.1000-1719.2020.11.036.
[24] 王怡茹,张一凡,韦婧,等. 桃仁红花煎通过抑制淋巴管增生改善ApoE-/-小鼠动脉粥样硬化的炎症反应[J]. 暨南大学学报(自然科学与医学版),2021,42(1):62-70. DOI:10.11778/j.jdxb.2021.01.009.
[25] 贾传宇,王舒阳,管海博. 赤芍总苷对脑出血大鼠神经功能损伤的改善及对脑组织中Treg/Th17比例的影响[J]. 中西医结合心脑血管病杂志,2023,21(2):272-275. DOI: 10.12102/j.issn.1672-1349.2023.02.013.
[26] 赵磊,袁庆,张彤,等. 基于PI3K/AKT通路探讨水蛭、地龙提取物对MCAO/R小鼠脑缺血半暗带神经元的保护作用[J]. 天津中医药,2022,39(8):1057-1063. DOI:10.11656/j.issn.1672-1519.2022.08.20.